MorphoSys AG (MPSYF)
USD 73.27
(0.0%)
USD 73.27
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 179.92 Million EUR | -21.65% |
| 2022 | 229.64 Million EUR | 55.8% |
| 2021 | 147.4 Million EUR | -53.72% |
| 2020 | 318.52 Million EUR | 433.81% |
| 2019 | 59.67 Million EUR | -20.06% |
| 2018 | 74.64 Million EUR | 11.82% |
| 2017 | 66.75 Million EUR | 34.47% |
| 2016 | 49.64 Million EUR | -53.23% |
| 2015 | 106.14 Million EUR | 66.11% |
| 2014 | 63.9 Million EUR | -18.0% |
| 2013 | 77.93 Million EUR | 50.11% |
| 2012 | 51.91 Million EUR | -44.62% |
| 2011 | 93.75 Million EUR | 17.56% |
| 2010 | 79.75 Million EUR | 7.37% |
| 2009 | 74.28 Million EUR | 15.15% |
| 2008 | 64.5 Million EUR | -7.73% |
| 2007 | 69.9 Million EUR | 14.59% |
| 2006 | 61 Million EUR | 481.44% |
| 2005 | 10.49 Million EUR | -52.26% |
| 2004 | 21.97 Million EUR | 43.57% |
| 2003 | 15.3 Million EUR | -8.64% |
| 2002 | 16.75 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 23.67 Million EUR | -46.83% |
| 2023 Q1 | 41.33 Million EUR | -37.61% |
| 2023 Q4 | 44.52 Million EUR | -8.58% |
| 2023 Q3 | 48.7 Million EUR | 7.12% |
| 2023 FY | 179.92 Million EUR | -21.65% |
| 2023 Q2 | 45.46 Million EUR | 9.99% |
| 2022 Q3 | 87.6 Million EUR | 107.58% |
| 2022 Q4 | 66.24 Million EUR | -24.38% |
| 2022 Q1 | 33.6 Million EUR | -22.58% |
| 2022 FY | 229.64 Million EUR | 55.8% |
| 2022 Q2 | 42.19 Million EUR | 25.59% |
| 2021 Q2 | 28.1 Million EUR | -33.32% |
| 2021 FY | 147.4 Million EUR | -53.72% |
| 2021 Q3 | 33.76 Million EUR | 20.15% |
| 2021 Q1 | 42.14 Million EUR | 58.27% |
| 2021 Q4 | 43.4 Million EUR | 28.54% |
| 2020 Q1 | 247.96 Million EUR | 2416.08% |
| 2020 Q4 | 26.62 Million EUR | 45.72% |
| 2020 Q3 | 18.27 Million EUR | 63.06% |
| 2020 FY | 318.52 Million EUR | 433.81% |
| 2020 Q2 | 11.2 Million EUR | -95.48% |
| 2019 Q4 | 9.85 Million EUR | -14.32% |
| 2019 Q1 | 8.57 Million EUR | -10.56% |
| 2019 Q2 | 29.73 Million EUR | 246.62% |
| 2019 FY | 59.67 Million EUR | -20.06% |
| 2019 Q3 | 11.5 Million EUR | -61.32% |
| 2018 Q1 | 2.79 Million EUR | -90.06% |
| 2018 Q4 | 9.59 Million EUR | -82.28% |
| 2018 Q2 | 8.12 Million EUR | 190.3% |
| 2018 FY | 74.64 Million EUR | 11.82% |
| 2018 Q3 | 54.13 Million EUR | 566.23% |
| 2017 Q1 | 11.84 Million EUR | -9.06% |
| 2017 FY | 66.75 Million EUR | 34.47% |
| 2017 Q4 | 28.15 Million EUR | 87.11% |
| 2017 Q3 | 15.04 Million EUR | 28.08% |
| 2017 Q2 | 11.74 Million EUR | -0.77% |
| 2016 Q2 | 12.16 Million EUR | 0.55% |
| 2016 FY | 49.64 Million EUR | -53.23% |
| 2016 Q4 | 13.02 Million EUR | 4.44% |
| 2016 Q3 | 12.46 Million EUR | 2.51% |
| 2016 Q1 | 12.09 Million EUR | -1.77% |
| 2015 Q4 | 12.31 Million EUR | 8.95% |
| 2015 FY | 106.14 Million EUR | 66.11% |
| 2015 Q3 | 11.3 Million EUR | -7.33% |
| 2015 Q2 | 12.19 Million EUR | -82.68% |
| 2015 Q1 | 70.41 Million EUR | 313.45% |
| 2014 Q1 | 15.87 Million EUR | 10.5% |
| 2014 FY | 63.9 Million EUR | -18.0% |
| 2014 Q4 | 17.03 Million EUR | 3.85% |
| 2014 Q3 | 16.39 Million EUR | 11.79% |
| 2014 Q2 | 14.67 Million EUR | -7.6% |
| 2013 Q4 | 14.36 Million EUR | -6.44% |
| 2013 Q2 | 31.31 Million EUR | 85.06% |
| 2013 FY | 77.93 Million EUR | 50.11% |
| 2013 Q1 | 16.91 Million EUR | 115.37% |
| 2013 Q3 | 15.35 Million EUR | -50.95% |
| 2012 Q1 | 14.43 Million EUR | -6.81% |
| 2012 Q2 | 15.32 Million EUR | 6.13% |
| 2012 Q3 | 14.29 Million EUR | -6.68% |
| 2012 Q4 | 7.85 Million EUR | -45.06% |
| 2012 FY | 51.91 Million EUR | -44.62% |
| 2011 Q1 | 46.74 Million EUR | 107.95% |
| 2011 FY | 93.75 Million EUR | 17.56% |
| 2011 Q2 | 16.12 Million EUR | -65.49% |
| 2011 Q4 | 15.49 Million EUR | 0.68% |
| 2011 Q3 | 15.38 Million EUR | -4.59% |
| 2010 Q4 | 22.47 Million EUR | 27.57% |
| 2010 FY | 79.75 Million EUR | 7.37% |
| 2010 Q1 | 18.83 Million EUR | -13.4% |
| 2010 Q2 | 20.81 Million EUR | 10.51% |
| 2010 Q3 | 17.62 Million EUR | -15.36% |
| 2009 Q3 | 17.97 Million EUR | 5.17% |
| 2009 Q4 | 21.75 Million EUR | 21.04% |
| 2009 FY | 74.28 Million EUR | 15.15% |
| 2009 Q2 | 17.08 Million EUR | -2.2% |
| 2009 Q1 | 17.47 Million EUR | 0.0% |
| 2008 FY | 64.5 Million EUR | -7.73% |
| 2007 FY | 69.9 Million EUR | 14.59% |
| 2006 FY | 61 Million EUR | 481.44% |
| 2005 FY | 10.49 Million EUR | -52.26% |
| 2004 FY | 21.97 Million EUR | 43.57% |
| 2003 FY | 15.3 Million EUR | -8.64% |
| 2002 FY | 16.75 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -1099.569% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -5800135.751% |
| SQZ Biotechnologies Company | 9.79 Million USD | -1737.077% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -1437.018% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | -51.06% |
| Mesoblast Limited | -35.16 Million USD | 611.611% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 526961.824% |
| Genus plc | 178.7 Million USD | -0.685% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -43766.081% |
| Marizyme, Inc. | 457.7 Thousand USD | -39210.143% |
| ContraFect Corporation | -154 Thousand USD | 116933.32% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 1635766.482% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 359946.626% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -234294.175% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -273639.218% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 46531.703% |
| MultiCell Technologies, Inc. | 49.32 USD | -364807915.004% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -346.848% |
| EV Biologics, Inc. | 48.9 Thousand USD | -367841.335% |
| Q BioMed Inc. | -8988.00 USD | 2001917.012% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -536.784% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 1166615.255% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 18.255% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -256933.304% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 144906.33% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -289044.912% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 3633446.385% |
| Arch Therapeutics, Inc. | -2439.00 USD | 7377029.602% |
| IMV Inc. | -962.29 Thousand USD | 18797.255% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -127959.298% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 184608.345% |
| GB Sciences, Inc. | -624.00 USD | 28833964.263% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 209245.061% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 97.62% |
| Halberd Corporation | -208.00 USD | 86501692.788% |
| Enzolytics Inc. | 30.7 Thousand USD | -585816.742% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -13157.506% |
| SYBLEU INC | 11.69 Thousand USD | -1538232.019% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -37194.985% |
| argenx SE | 1.1 Billion USD | 83.768% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 797.431% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -29042.853% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 56.068% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 2031754.393% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -305.618% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 15861.013% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -18111.212% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -1772.056% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 214680.154% |
| BioStem Technologies, Inc. | 15.42 Million USD | -1066.451% |
| ONE Bio Corp. | 20.12 Million USD | -794.009% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 1520364.58% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 372928.515% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -101804.912% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -101804.912% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 35069.838% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 28653.002% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 620525.217% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -39879.138% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 56412.792% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -3804.586% |
| Bioxytran, Inc. | -8285.00 USD | 2171775.474% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 48336.813% |
| Neutra Corp. | 14.33 Thousand USD | -1255032.982% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 219518.674% |
| PureTech Health plc | -1.6 Million USD | 11324.162% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 18070.12% |
| IXICO plc | 3.27 Million USD | -5402.242% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 26025.549% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 10145.969% |
| CSL Limited | 7.7 Billion USD | 97.665% |
| Cellectis S.A. | 18 Thousand USD | -999473.961% |